BioSpace News Archive

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the publication of its Phase 3 CARES 310 study results in The Lancet.

Motif Neurotech , a clinical-stage company developing minimally invasive bioelectronics for mental health, announces the appointment of Steven Goetz as Chief Technology Officer.

NANO-X IMAGING LTD today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,142,858 of the Company’s ordinary shares.

Marius Pharmaceuticals is proud to announce the launch of their disease state awareness website, ReThink Testosterone.

Aptitude Medical Systems has been awarded a significant grant from the Bill & Melinda Gates Foundation to develop point-of-care diagnostic tests for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023.

AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).

Talis Biomedical Corporation today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share.